Prophylactic Treatment With Atorvastatin for Episodic Migraine.

Summary

The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.

Conditions

• Episodic Migraine

Interventions

DRUG

Atorvastatin 40mg

Each tablet will be taken once daily for 84 days.

DRUG

Placebo

Each tablet will be taken once daily for 84 days

DRUG

Atorvastatin 20mg

Each tablet will be taken once daily for 84 days.

Sponsors & Collaborators

• Haukeland University Hospital

  collaborator OTHER

• University Hospital of North Norway

  collaborator OTHER

• University Hospital, Akershus

  collaborator OTHER

• Ullevaal University Hospital

  collaborator OTHER

• St. Olavs Hospital

  lead OTHER

Principal Investigators

• Marte-Helene Bjørk, Professor · Haukeland University Hospital

• Kjersti G Vetvik, Ph.d. · University Hospital, Akershus

• Bendik S Winsvold, Post.doc. · Oslo University Hospital, Ullevål

• Anne H Aamodt, Senior researcher · Oslo University Hospital

• Lise R Øie, Post.doc. · St. Olavs Hospital

• Linn H Steffensen, Associate Professor II · University Hospital Northern Norway

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-05-01

Primary Completion

2028-12-31

Completion

2029-02-28

Countries

• Norway

Study Locations